<DOC>
	<DOC>NCT01518309</DOC>
	<brief_summary>This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).</brief_summary>
	<brief_title>An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>Inclusion Criteria Patients of any age, male or female with a clinical diagnosis of idiopathic Parkinson's disease, who participated in a previous (Phase II) clinical trial that evaluated pimavanserin Patients who may, in the opinion of the treating physician, benefit from continued therapy with pimavanserin Patient is willing and able to provide consent Exclusion Criteria Female patient of childbearing potential Patient has a clinically significant concurrent medical illness Patient is judged by the treating physician to be inappropriate for the study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>